Titan Medical (TMDIF) Competitors

$0.20 0.00 (-2.21%)

As of 05/22/2026

TMDIF vs. SPAI, STIM, PYPD, SKIN, and STSS

Should you buy Titan Medical stock or one of its competitors? MarketBeat compares Titan Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Titan Medical include Safe Pro Group (SPAI), Neuronetics (STIM), PolyPid (PYPD), Beauty Health (SKIN), and Sharps Technology (STSS). These companies are all part of the "medical equipment" industry.

How does Titan Medical compare to Safe Pro Group?

Titan Medical (NASDAQ:TMDIF) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Titan Medical has a net margin of 0.00% compared to Safe Pro Group's net margin of -800.91%. Titan Medical's return on equity of -82.31% beat Safe Pro Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Safe Pro Group	-800.91%	-119.17%	-107.17%

Titan Medical has higher revenue and earnings than Safe Pro Group. Safe Pro Group is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08
Safe Pro Group	$610K	144.86	-$14.32M	-$0.71	N/A

In the previous week, Safe Pro Group had 15 more articles in the media than Titan Medical. MarketBeat recorded 15 mentions for Safe Pro Group and 0 mentions for Titan Medical. Safe Pro Group's average media sentiment score of 0.43 beat Titan Medical's score of 0.00 indicating that Safe Pro Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Safe Pro Group	Neutral

Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3, meaning that its share price is 200% more volatile than the broader market.

Safe Pro Group has a consensus target price of $10.00, indicating a potential upside of 136.41%. Given Safe Pro Group's stronger consensus rating and higher probable upside, analysts plainly believe Safe Pro Group is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Safe Pro Group	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.60

0.0% of Titan Medical shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 54.8% of Safe Pro Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Safe Pro Group beats Titan Medical on 9 of the 17 factors compared between the two stocks.

How does Titan Medical compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Titan Medical has a net margin of 0.00% compared to Neuronetics' net margin of -24.48%. Titan Medical's return on equity of -82.31% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Titan Medical	N/A	-82.31%	-51.47%

Neuronetics presently has a consensus price target of $3.00, indicating a potential upside of 150.00%. Given Neuronetics' stronger consensus rating and higher probable upside, research analysts plainly believe Neuronetics is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.56	-$39M	-$0.54	N/A
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08

Neuronetics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, Neuronetics had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for Neuronetics and 0 mentions for Titan Medical. Neuronetics' average media sentiment score of 1.42 beat Titan Medical's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Positive
Titan Medical	Neutral

Summary

Neuronetics beats Titan Medical on 9 of the 16 factors compared between the two stocks.

How does Titan Medical compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

PolyPid presently has a consensus price target of $12.25, indicating a potential upside of 144.02%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08

In the previous week, PolyPid had 9 more articles in the media than Titan Medical. MarketBeat recorded 9 mentions for PolyPid and 0 mentions for Titan Medical. PolyPid's average media sentiment score of 0.03 beat Titan Medical's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Neutral
Titan Medical	Neutral

PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Titan Medical's return on equity of -82.31% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Titan Medical	N/A	-82.31%	-51.47%

Summary

PolyPid beats Titan Medical on 8 of the 14 factors compared between the two stocks.

How does Titan Medical compare to Beauty Health?

Beauty Health (NASDAQ:SKIN) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Beauty Health had 16 more articles in the media than Titan Medical. MarketBeat recorded 16 mentions for Beauty Health and 0 mentions for Titan Medical. Beauty Health's average media sentiment score of 0.90 beat Titan Medical's score of 0.00 indicating that Beauty Health is being referred to more favorably in the media.

Company	Overall Sentiment
Beauty Health	Positive
Titan Medical	Neutral

Beauty Health presently has a consensus price target of $2.02, suggesting a potential upside of 193.73%. Given Beauty Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Beauty Health is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beauty Health	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has lower revenue, but higher earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beauty Health	$300.80M	0.30	-$9.52M	-$0.17	N/A
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08

Beauty Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

93.3% of Beauty Health shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 40.3% of Beauty Health shares are held by insiders. Comparatively, 0.0% of Titan Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Titan Medical has a net margin of 0.00% compared to Beauty Health's net margin of -2.03%. Beauty Health's return on equity of -9.38% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beauty Health	-2.03%	-9.38%	-1.21%
Titan Medical	N/A	-82.31%	-51.47%

Summary

Beauty Health beats Titan Medical on 10 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Sharps Technology?

Titan Medical (NASDAQ:TMDIF) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Titan Medical's return on equity of -82.31% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Sharps Technology	N/A	-157.91%	-154.40%

Titan Medical has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	1.32	$6.95M	$0.05	4.08
Sharps Technology	$200K	383.00	-$282.50M	-$1.63	N/A

In the previous week, Titan Medical's average media sentiment score of 0.00 beat Sharps Technology's score of -0.63 indicating that Titan Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Titan Medical	Neutral
Sharps Technology	Negative

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Sharps Technology has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market.

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 1.2% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Titan Medical beats Sharps Technology on 7 of the 12 factors compared between the two stocks.

Get Titan Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDIF vs. The Competition

Export

Metric	Titan Medical	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.25M	$53.33M	$6.46B	$12.34B
Dividend Yield	N/A	1.08%	2.76%	5.28%
P/E Ratio	-0.16	18.68	21.00	25.66
Price / Sales	1.32	37.51	562.18	86.31
Price / Cash	0.02	18.87	43.49	56.67
Price / Book	0.19	16.15	10.41	7.14
Net Income	$6.95M	-$20.25M	$3.57B	$335.98M
7 Day Performance	1.44%	2.27%	6.40%	4.11%
1 Month Performance	-38.21%	-12.00%	3.54%	2.52%
1 Year Performance	-25.96%	-2.39%	34.14%	35.04%

Titan Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDIF Titan Medical	N/A	$0.20 -2.2%	N/A	-26.0%	$23.25M	$17.63M	N/A	50	Gap Down
SPAI Safe Pro Group	3.1442 of 5 stars	$4.35 flat	$10.00 +129.9%	+48.4%	$90.87M	$610K	N/A	11	Gap Up High Trading Volume
STIM Neuronetics	3.6042 of 5 stars	$1.28 flat	$3.00 +134.4%	-69.9%	$89.08M	$149.16M	N/A	180	Positive News
PYPD PolyPid	3.3633 of 5 stars	$4.46 flat	$12.25 +174.7%	+80.6%	$85.10M	N/A	N/A	80	Gap Down High Trading Volume
SKIN Beauty Health	2.7628 of 5 stars	$0.64 flat	$2.32 +260.4%	-57.3%	$83.42M	$296.12M	N/A	1,030	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDIF) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Titan Medical (TMDIF) Competitors

TMDIF vs. SPAI, STIM, PYPD, SKIN, and STSS

How does Titan Medical compare to Safe Pro Group?

Summary

How does Titan Medical compare to Neuronetics?

Summary

How does Titan Medical compare to PolyPid?

Summary

How does Titan Medical compare to Beauty Health?

Summary

How does Titan Medical compare to Sharps Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Titan Medical (TMDIF) Competitors

TMDIF vs. SPAI, STIM, PYPD, SKIN, and STSS

How does Titan Medical compare to Safe Pro Group?

Is TMDIF or SPAI more profitable?

Which has better earnings & valuation, TMDIF or SPAI?

Does the media favor TMDIF or SPAI?

Which has more risk and volatility, TMDIF or SPAI?

Do analysts recommend TMDIF or SPAI?

Do institutionals & insiders believe in TMDIF or SPAI?

Summary

How does Titan Medical compare to Neuronetics?

Do institutionals and insiders have more ownership in STIM or TMDIF?

Is STIM or TMDIF more profitable?

Do analysts prefer STIM or TMDIF?

Which has higher valuation & earnings, STIM or TMDIF?

Which has more risk and volatility, STIM or TMDIF?

Does the media prefer STIM or TMDIF?

Summary

How does Titan Medical compare to PolyPid?

Do analysts rate PYPD or TMDIF?

Which has higher valuation & earnings, PYPD or TMDIF?

Does the media refer more to PYPD or TMDIF?

Which has more risk & volatility, PYPD or TMDIF?

Do institutionals & insiders believe in PYPD or TMDIF?

Is PYPD or TMDIF more profitable?

Summary

How does Titan Medical compare to Beauty Health?

Does the media prefer SKIN or TMDIF?

Do analysts recommend SKIN or TMDIF?

Which has better valuation & earnings, SKIN or TMDIF?

Which has more volatility & risk, SKIN or TMDIF?

Do institutionals & insiders hold more shares of SKIN or TMDIF?

Is SKIN or TMDIF more profitable?

Summary

How does Titan Medical compare to Sharps Technology?

Do analysts rate TMDIF or STSS?

Is TMDIF or STSS more profitable?

Which has stronger valuation & earnings, TMDIF or STSS?

Does the media refer more to TMDIF or STSS?

Which has more volatility & risk, TMDIF or STSS?

Do insiders and institutionals believe in TMDIF or STSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools